Application of T cell subsets as diagnostic markers for Helicobacter pylori and diagnostic devices

By detecting the substances of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells, he developed Helicobacter pylori infection diagnosis products and devices, solving the problem of cumbersome and time-consuming existing detection methods, and achieving rapid and simple Helicobacter pylori infection. High-throughput detection improves detection efficiency and accuracy.

CN118518873BActive Publication Date: 2024-11-12SECOND MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410977490.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-22
Publication Date
2024-11-12
Estimated Expiration
2044-07-22

AI Technical Summary

Technical Problem

Existing Helicobacter pylori detection methods such as C13 air blowing experiments are cumbersome and time-consuming, and cannot effectively screen most carriers, resulting in worsening infection transmission and need to simplify and improve detection efficiency.

Method used

By detecting the substances of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells, helicobacter pylori infection diagnosis products and devices were developed, and rapid screening was performed using flow cytometry detection and computer-readable media, combining the proportion of specific lymphocyte subpopulations. Make a diagnosis.

Benefits of technology

It realizes rapid, simple and high-throughput detection of Helicobacter pylori infection, effectively evaluates individual immune response capabilities, simplifies the diagnostic process, and improves detection efficiency and accuracy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118518873B_ABST
    Figure CN118518873B_ABST
Patent Text Reader

Abstract

The present invention provides an application of a T cell subset as a diagnostic marker for Helicobacter pylori and a diagnostic device, and relates to the field of biotechnology. The present invention provides an application of a substance for detecting CD3+CD4+CX3CR1+CD45RA‑CD45RO+T cells in the preparation of a diagnostic product for Helicobacter pylori infection. The present invention finds a quantitative correlation between the content of CD3+CD4+CX3CR1+CD45RA‑CD45RO+T cells in a subject and the DOB value of a C13 air puff test result, and the cell subset can be used as a diagnostic marker for Helicobacter pylori infection, simplifying the diagnostic method for Helicobacter pylori infection and developing new diagnostic products.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to an application of a T cell subset as a diagnostic marker for Helicobacter pylori and a diagnostic device. Background Art

[0002] The following statements merely provide background information related to the present disclosure and do not necessarily constitute prior art.

[0003] Helicobacter pylori (H. pylori) is a spiral Gram-negative bacillus that colonizes the gastric mucosa and can cause a series of diseases such as gastritis, gastric ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. In 1994, the World Health Organization identified H. pylori as a Class I carcinogen for gastric cancer, and in 2021 it was listed as a clear carcinogen (15th Report on Carcinogens 2021.12). It is reported that H. pylori has infected more than half of the world's population. The immune response stimulated by H. pylori infection cannot effectively eliminate the bacteria, causing most infected people to be carriers for decades or for life.

[0004] The commonly used detection method at this stage, the C13 breath test, can detect the bacterial status of Helicobacter pylori, reflecting the individual's bacterial load and the vitality of the bacteria. Therefore, the C13 breath test is widely used clinically as a clinical test and diagnosis method for Helicobacter pylori infection. This method requires oral 13C urea and collects three breaths in total. The test time usually takes about 1 hour for the subject, and the steps are relatively cumbersome. A large number of carriers are not clear about their infection status, which undoubtedly aggravates the spread of Helicobacter pylori. Based on this, it is necessary to seek new diagnostic methods.

[0005] In view of this, the present invention is proposed. Summary of the invention

[0006] The purpose of the present invention is to provide an application of a substance for detecting CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells in the preparation of a Helicobacter pylori infection diagnosis product to simplify the Helicobacter pylori infection diagnosis method. Based on this application, the present invention also provides a Helicobacter pylori infection diagnosis device.

[0007] In order to solve the above technical problems, the present invention particularly adopts the following technical solutions:

[0008] In a first aspect, provided is the use of a substance for detecting CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells in the preparation of a diagnostic product for Helicobacter pylori infection.

[0009] In an optional embodiment, the product includes a detection reagent, a kit, an antibody chip, an antibody probe or a detection device.

[0010] In an alternative embodiment, the product includes a reagent for separating blood.

[0011] In an optional embodiment, the substance for detecting CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells includes CD3 antibody, CD4 antibody, CX3CR1 antibody, CD45RA antibody and CD45RO antibody.

[0012] In an optional embodiment, the substance for detecting CD3+CD4+CX3CR1+CD45RA-CD45RO+T also includes a reagent, a kit or a detection device for flow cytometry detection.

[0013] In a second aspect, a Helicobacter pylori infection diagnosis device is also provided, the diagnosis device comprising a detection module and a prediction and judgment module;

[0014] The detection module obtains the content of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells;

[0015] The prediction and judgment module includes a computer-readable medium recording judgment rules, and when the computer-readable medium is processed and executed, the CD3+CD4+CX3CR1+CD45RA-CD45RO+T cell content is compared with a threshold value. When the CD3+CD4+CX3CR1+CD45RA-CD45RO+T cell content is within the range defined by the threshold value, it is determined that the subject is in a state of Helicobacter pylori infection.

[0016] In an optional embodiment, the threshold value includes a cut-off value of the CD3+CD4+CX3CR1+CD45RA-CD45RO+T cell content obtained from a group of patients infected with Helicobacter pylori, and the DOB value of the patients infected with Helicobacter pylori is determined by the C13 insufflation method.

[0017] In an optional embodiment, obtaining the content of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells includes obtaining the proportion of CD3+CD4+CX3CR1+CD45RA-CD45RO+T in CD3+CD4+T cells in the peripheral blood of the subject;

[0018] The cut-off value is the proportion of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells in the CD3+CD4+T cells in the peripheral blood of the subject.

[0019] In an optional implementation, the cut-off value is 3.63%.

[0020] In an optional embodiment, the detection module includes an antibody composition and a flow cytometric detection device;

[0021] The antibody composition comprises CD3 antibody, CD4 antibody, CX3CR1 antibody, CD45RA antibody and CD45RO antibody.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] The present invention finds that CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells have a quantitative correlation with the results of the C13 air blowing test of Helicobacter pylori, and the T lymphocyte subset reflects the individual's immune status against Helicobacter pylori, which is conducive to evaluating the individual's direct immune response ability against Helicobacter pylori. Based on the quantitative correlation between CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells and the results of the C13 air blowing test of Helicobacter pylori, the cell subset can be used as a diagnostic marker for Helicobacter pylori infection, and Helicobacter pylori infected persons can be screened by evaluating specific lymphocyte subsets in the sample. The detection method only needs to obtain the content of specific lymphocyte subsets in the sample, which can be carried out simultaneously with other examinations, saving time and labor, and is conducive to screening the Helicobacter pylori infection status of the general population. Using CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells as diagnostic markers has the advantages of being effective, safe, rapid and simple, which facilitates high-throughput testing in clinical practice and the development of high-throughput testing products. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0025] Figure 1 The CD3+CD4+CX3CR1+T cell content in the gastric mucosa of mice in the Helicobacter pylori infection group and the control group in Example 1;

[0026] Figure 2 is the linear correlation between the Helicobacter pylori colonization in the gastric mucosa of mice and the CD3+CD4+CX3CR1+T cell response in the gastric mucosa in Example 2;

[0027] Figure 3is the correlation between the ratio of CD3+CD4+CX3CR1+CD45RA-CD45RO+T in CD3+CD4+ T cells in peripheral blood and DOB value;

[0028] Figure 4 is the ratio of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells in the peripheral blood of H. pylori negative volunteers;

[0029] Figure 5 is the ratio of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells in the peripheral blood of volunteers with positive Helicobacter pylori;

[0030] Figure 6 The ROC curve was constructed with the proportion of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells in peripheral blood as 3.63% as the cut-off value. DETAILED DESCRIPTION

[0031] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0032] CD4+ T lymphocytes play an important role in the fight against Helicobacter pylori infection, and the number of CD4+ T cells that evaluate the direct immune response to Helicobacter pylori is intentional. The present invention found through experiments that Helicobacter pylori infection in the test animals can stimulate the gastric mucosa to produce CD3+CD4+CX3CR1+T cells. It was further verified that CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells were correlated with the DOB value of the test results of the C13 air blowing method, a clinical test and diagnosis method for Helicobacter pylori infection, and a ROC curve was constructed to verify that the content of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells can be used as a diagnostic standard for Helicobacter pylori infection.

[0033] Based on the above findings, the first aspect of the present invention provides the use of a substance for detecting CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells in the preparation of a product for diagnosing Helicobacter pylori infection.

[0034] In an optional embodiment, the material for detecting CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells includes a material for detecting CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells in peripheral blood.

[0035] In an optional embodiment, the substance for detecting CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells includes a substance for detecting the proportion of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells in peripheral blood CD3+CD4+T cells. Preferably, the subject to be detected includes a human.

[0036] In an optional embodiment, the substance for detecting CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells includes CD3 antibody, CD4 antibody, CX3CR1 antibody, CD45RA antibody and CD45RO antibody.

[0037] In an optional embodiment, the antibodies in the substance for detecting CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells are labeled with markers, and preferably different antibodies are labeled with different markers.

[0038] In an optional embodiment, different antibodies in the material for detecting CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells are labeled with different fluorescent molecules, and the fluorescent molecules include but are not limited to one or more of FAM, FITC, TET, HEX, JOE20, APC, rhodamine dyes (Rhodamine dyes such as R110, TA MRA, TexasRed, etc.), ROX, AlexaFluor dyes and cyanine dyes (such as Cy2, Cy3, Cy3.5, Cy3b, Cy5, Cy5.5, Cy7, Cy7.5).

[0039] In an optional embodiment, the product includes a detection reagent, a kit, an antibody chip, an antibody probe or a detection device.

[0040] In an optional embodiment, the product includes a reagent, a kit or a detection device for flow cytometry detection.

[0041] In an alternative embodiment, the product includes a reagent for separating blood.

[0042] In an optional embodiment, the product further includes optional reagents for detection known in the art, including but not limited to one or more of buffers, eluents, washing solutions, lysates, negative controls, positive controls, standards, quality control products and blank controls.

[0043] In a second aspect, a Helicobacter pylori infection diagnosis device is also provided, the diagnosis device comprising a detection module and a prediction and judgment module;

[0044] The detection module obtains the content of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells;

[0045] The prediction and judgment module includes a computer-readable medium recording judgment rules, and when the computer-readable medium is processed and executed, a program is implemented to compare the CD3+CD4+CX3CR1+CD45RA-CD45RO+T cell content with a threshold value. When the CD3+CD4+CX3CR1+CD45RA-CD45RO+T cell content is within the range defined by the threshold value, it is determined that the subject is in a state of Helicobacter pylori infection.

[0046] In an optional embodiment, the detection module obtains the CD3+CD4+CX3CR1+CD45RA-CD45RO+T cell content in plasma, preferably obtains the CD3+CD4+CX3CR1+CD45RA-CD45RO+T cell content in peripheral blood, and further preferably obtains the proportion of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells in peripheral blood.

[0047] In an optional embodiment, the threshold value includes a cut-off value of the CD3+CD4+CX3CR1+CD45RA-CD45RO+T cell content obtained from a group of patients infected with Helicobacter pylori, and the DOB value of the patients infected with Helicobacter pylori is determined by the C13 insufflation method.

[0048] In an optional embodiment, when the DOB value is greater than or equal to 4, the subject is determined to be a patient infected with Helicobacter pylori.

[0049] In an optional implementation, the cut-off value is 3.63%.

[0050] In an optional embodiment, the detection module obtains the proportion of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells in the CD3+CD4+T cells in the peripheral blood, and the prediction and judgment module compares the value of the proportion with the cut-off value. When the value of the proportion does not exceed the set cut-off value, the prediction and judgment module outputs a judgment result that the sample to be tested is a Helicobacter pylori-positive subject.

[0051] In an optional embodiment, the detection module comprises an antibody composition and a flow cytometric detection device. The antibody composition comprises CD3 antibody, CD4 antibody, CX3CR1 antibody, CD45RA antibody and CD45RO antibody.

[0052] In an alternative embodiment, different antibodies in the antibody composition are labeled with different markers.

[0053] In an optional embodiment, the device further comprises a sample preprocessing module, which separates total nucleated cells in peripheral blood.

[0054] The present invention is further described below by means of specific examples. However, it should be understood that these examples are only used for more detailed description and should not be construed as limiting the present invention in any form.

[0055] Example 1

[0056] Helicobacter pylori infection stimulates CD3+CD4+CX3CR1+ T cell responses in mouse gastric mucosa

[0057] 1. Experimental methods:

[0058] 1. Preparation of Helicobacter pylori infection mouse model:

[0059] Experimental animals: BALB / c mice, female, 6-8 weeks old, 5 mice in each group.

[0060] Infection scheme: Helicobacter pylori infection group: 1.0×10 9 CFU Helicobacter pylori was administered intragastrically once a day for 4 consecutive days; the control group was administered intragastrically with an equal amount of PBS.

[0061] 1.2 Detection of CD3+CD4+CX3CR1+T cells in mouse gastric mucosa:

[0062] (1) Isolation of mouse gastric mucosal lymphocytes:

[0063] Mouse stomach tissue was dissected along the greater and lesser curvatures of the stomach and gently washed twice with sterile PBS to remove food residues. Then, 10 mL of Hank's balanced salt solution (HBSS, without Ca2+) was added. 2+ ,Mg 2+ ) containing 1mM dithiothreitol (DTT), 1mM ethylenediaminetetraacetic acid (EDTA), and 2% fetal calf serum (FCS) and incubated at 37°C for 45min. Then, the resulting mixture was passed through a sterile steel mesh to remove undigested tissue to obtain a single-cell suspension. The digested single-cell suspension was washed twice with sterile PBS and set aside.

[0064] (2) Flow cytometry detection

[0065] The above-isolated lymphocyte suspension was stained with fluorescently labeled monoclonal antibodies. The antibodies used were APClabeled anti-mouse CD3, APC / Cy7 labeled anti-mouse CD4, and PerCP / Cy5.5 labeledanti-mouse CX3CR1. After staining, the cells were washed with PBS, resuspended in PBS, and detected by flow cytometry.

[0066] 2. Experimental results:

[0067] The experimental results are as follows Figure 1 As shown, it can be seen that the content of CD3+CD4+CX3CR1+T cells in the gastric mucosa of Helicobacter pylori-infected mice was significantly increased compared with the control group, indicating that CD3+CD4+CX3CR1+T cells are expected to be used as a diagnostic marker for Helicobacter pylori-positive samples.

[0068] Example 2

[0069] Mouse gastric mucosal CD3+CD4+CX3CR1+ T cells play a protective role in Helicobacter pylori infection

[0070] 1. Experimental methods:

[0071] 1. Isolation of CX3CR1+ T cells from mouse peripheral blood

[0072] Experimental animals: 10 female C57BL / 6 mice with CX3CR1 gene tagged with GFP tag, 8 weeks old.

[0073] Sorting scheme: Use the orbital blood sampling method to obtain peripheral blood of mice, and take about 1 ml of whole blood from each mouse. Dilute with PBS 1:1, add to a 15 ml centrifuge tube containing ficoll solution, centrifuge at 2000 rpm for 20 minutes, and the speed is 3 (a total of 10 gears). After centrifugation, use a pipette to aspirate the middle white film layer, add 15 ml PBS and wash twice. Centrifuge at 1800 rpm at room temperature for 5 minutes to obtain a cell pellet. Use Beckman flow cytometer to sort CD3+CD4+CX3CR1+T cells. Every 10 4 Each cell was stored in 1 tube.

[0074] 2. Adoptive transfer of CD3+CD4+CX3CR1+ T cells

[0075] Experimental animals: C57BL / 6 mice, female, 6-8 weeks old, 8 mice.

[0076] Adoptive transfer scheme: The mice were divided into 4 groups, with 2 mice in each group. Group 3 was injected with 200 μl of cell suspension (containing 10 3CD3+CD4+CX3CR1+T cells) and the fourth group was injected with 200 μl of cell suspension (containing 10 4 CD3+CD4+CX3CR1+T cells) were injected into the tail vein of groups 1 and 2 with an equal amount of PBS.

[0077] 3. Preparation of Helicobacter pylori infection mouse model

[0078] Experimental animals: mice adopted with the above CD3+CD4+CX3CR1+ T cells.

[0079] Infection scheme: Helicobacter pylori infection group: Groups 2, 3, and 4 were treated with 1.0×10 7 CFU concentration of Helicobacter pylori was gavaged once a day for 4 consecutive days. Control group: Group 1 was gavaged with the same amount of PBS, with the same scheme as the first group.

[0080] 4. Detection of Helicobacter pylori in gastric mucosa of mice:

[0081] The amount of Helicobacter pylori colonization in the gastric mucosa of mice was detected by real-time quantitative RT-PCR method.

[0082] (1) Four weeks after infection, the mice were euthanized and their stomachs were removed by dissection.

[0083] (2) Cut the gastric tissue into pieces using surgical scissors and add 1 mL of sterile saline.

[0084] (3) The gastric tissue was further homogenized using a homogenizer under low temperature conditions. Helicobacter pylori DNA was then extracted using a bacterial genomic DNA extraction kit. The tissue homogenate was centrifuged at high speed and the supernatant was discarded.

[0085] (4) Add 200 μL of GA buffer to the precipitate to resuspend the tissue fragments. Then add 20 μL of proteinase K and mix well.

[0086] (5) Add GB buffer and vortex to mix.

[0087] (6) Incubate at 70°C for 10 minutes. When the solution becomes clear, centrifuge immediately.

[0088] (7) Add 220 μL of anhydrous ethanol, mix thoroughly, and centrifuge briefly until a flocculent precipitate is precipitated.

[0089] (8) Transfer the entire mixture to centrifuge column CB3 and centrifuge at high speed (13200 g) for 1 min.

[0090] (9) After washing with buffer GD and PW, transfer the centrifuge column to a new centrifuge tube and dry it.

[0091] (10) Add 200 μL of deionized water and let stand at room temperature for 2 minutes. Centrifuge at high speed for 1 minute and collect the filtrate, which is the aqueous solution of the target DNA.

[0092] (11) Take 2 μL of the above DNA solution and use the RT-PCR method to quantitatively detect Helicobacter pylori 16S rDNA. Use Helicobacter pylori 16S rDNA standards with different concentration gradients to make a standard curve, and set up positive and negative controls. Set up 3 replicates for each condition, and the average value is regarded as the DNA concentration of the test sample. The test result is multiplied by the dilution factor to obtain the colonization amount of Helicobacter pylori in each mouse stomach. The final result is expressed as a logarithm (log10).

[0093] The primers and probes used for Real-time RT-PCR are shown in the following table.

[0094] Table 1 Primer and probe sequences

[0095]

[0096] The real-time PCR reaction system is as follows:

[0097] Table 2 Real-time PCR reaction system

[0098]

[0099] Real-time PCR reaction conditions are as follows:

[0100] Table 3 Real-time PCR reaction conditions

[0101]

[0102] 2. Experimental results:

[0103] The experimental results are as follows Figure 2 As shown in the figure, compared with the control group, adoptive CD3+CD4+CX3CR1+T cells can reduce the colonization of Helicobacter pylori; the more CD3+CD4+CX3CR1+T cells there are, the lower the colonization of Helicobacter pylori is, indicating that CD3+CD4+CX3CR1+T cells play an antibacterial protective function in Helicobacter pylori infection.

[0104] Example 3

[0105] Examples 1 and 2 found that the content of CD3+CD4+CX3CR1+T cells in mice infected with Helicobacter pylori was related to the infection level of Helicobacter pylori. This example further verified the diagnostic ability of CD45RA-CD45RO+ cells in CD3+CD4+CX3CR1+T cells for Helicobacter pylori:

[0106] 1. Experimental methods:

[0107] Volunteers were recruited to participate in the experiment, and they were required to fast for 8 hours to test the DOB value of the C13 experiment. The first breathing test was a blank test, and then the time was calculated immediately after taking a 13C urea capsule and a cup of about 250mL water orally. The second breath was exhaled into the second test tube after 20 minutes, and the third exhalation was exhaled into the third tube after 30 minutes. Exhale completely and forcefully into the test tube. The whole process takes about 45 minutes. The DOB value was obtained by testing on the machine.

[0108] Peripheral blood was drawn by experienced nurses to detect lymphocyte subsets: 100 μL of whole blood was taken from each sample, 2 mL of red blood cell lysis buffer was added, and red blood cells were lysed at room temperature in the dark for 15 minutes. The supernatant was centrifuged and washed twice with 2 mL of PBS, and the cell pellet was obtained by centrifugation at 2000 rpm for 5 minutes at room temperature. 1 μL of zombie was added to 50 μL of PBS to form a 50 μL system, and 50 μL of the mixed system was used to resuspend the washed cells and stain them at room temperature for 20 minutes. 2 mL of PBS was added to wash the cells twice, and the cell pellet was obtained by centrifugation at 2000 rpm for 5 minutes at room temperature. 1 μL of CD3\CD4\CX3CR1\CD45RA\CD45RO flow cytometer fluorescent antibodies were added to 50 μL of PBS to form a 50 μL system. 50 μL of the mixed system was used to resuspend the washed cells and stain them at room temperature for 20 minutes. 2 mL of PBS was added to wash the cells twice, and the cell pellet was obtained by centrifugation at 2000 rpm for 5 minutes at room temperature. 180 μL of PBS was used to resuspend the cells for detection. 100 μL of resuspended cells were quantitatively collected and the data were analyzed.

[0109] 2. Experimental results:

[0110] The DOB value obtained from the volunteer test was used as the horizontal axis, and the corresponding ratio of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells in CD3+CD4+T cells in peripheral blood was used as the vertical axis to construct a correlation curve. The results are as follows Figure 3 As shown in Table 4, it can be seen that the proportion of CD3+CD4+CX3CR1+CD45RA-CD45RO+T in CD3+CD4+ T cells in human peripheral blood is correlated with the DOB results, indicating that the proportion of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells can be used as a diagnostic marker for diagnosing Helicobacter pylori infection.

[0111] Table 4 Statistical results of the correlation between the proportion of peripheral blood CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells in CD3+CD4+T cells and DOB value

[0112]

[0113] In the above table, ** indicates that the correlation is significant at the 0.01 level (two-tailed).

[0114] A DOB value of less than 4 was used to confirm that the volunteers were negative for Helicobacter pylori. The CD3+CD4+CX3CR1+CD45RA-CD45RO+T cell ratio of Helicobacter pylori negative volunteers with a DOB value of 0.9 was, for example, Figure 4 As shown, it is 9.99%; the Helicobacter pylori-positive samples were confirmed to be DOB values ​​greater than or equal to 4. The CD3+CD4+CX3CR1+CD45RA-CD45RO+T cell ratio of Helicobacter pylori-positive volunteers with a DOB value of 30.6 was, for example, Figure 5 As shown, it is 1.93%, which again confirms that the proportion of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells can distinguish between Helicobacter pylori-negative and -positive volunteers.

[0115] The ROC curve was further constructed with the CD3+CD4+CX3CR1+CD45RA-CD45RO+T cell ratio of 3.63% as the cut-off value, as shown in Figure 6 As shown, when the cut-off value was 3.63%, the diagnostic sensitivity was 66.7% and the specificity was 90.48%, indicating that CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells can be used as a diagnostic marker to diagnose whether the subject is infected with Helicobacter pylori.

[0116] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A Helicobacter pylori infection diagnostic device, characterized in that: It includes sample preprocessing module, detection module and prediction and judgment module; The sample preprocessing module separates total nucleated cells in peripheral blood; The detection module obtains the proportion of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells in CD3+CD4+T cells in the subject's peripheral blood; The prediction and judgment module includes a computer-readable medium having a judgment rule recorded thereon, and when the computer-readable medium is processed and executed, the value of the proportion of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells in the CD3+CD4+T cells in the subject's peripheral blood is compared with a threshold value, and when the value of the proportion does not exceed the set threshold value, the prediction and judgment module outputs a judgment result that the sample to be tested is from a Helicobacter pylori-positive subject; The threshold value is a cut-off value of the proportion of CD3+CD4+CX3CR1+CD45RA-CD45RO+T cells in CD3+CD4+T cells obtained from a group of patients infected with Helicobacter pylori, and the DOB value of the patients infected with Helicobacter pylori is determined by the C13 insufflation method.

2. The diagnostic device according to claim 1, characterized in that The cut-off value is 3.63%.

3. The diagnostic device according to claim 1 or 2, characterized in that: The detection module includes an antibody composition and a flow cytometric detection device; The antibody composition comprises CD3 antibody, CD4 antibody, CX3CR1 antibody, CD45RA antibody and CD45RO antibody.